Schizophrenia Is a Complex, Long-term Medical Illness for Which Ongoing Treatment Is Recommended

Schizophrenia is a highly heterogeneous disease that affects ~1.1% of the US population, characterized by episodes of psychosis and periods of remission

Early Phase

Onset of Disease

Diagnosis typically occurs during late adolescence to early 20s in males and early 20s to early 30s in females

> Similar lifetime prevalence between men and women







More severe negative symptoms

More cognitive impairment

Worse social functioning

Higher rates of comorbid substance use disorders

Prominent affective symptoms (depression, anxiety)

Milder early-course illness severity

Better social functioning

Lower relapse rates

Initial diagnosis and treatment may be delayed due to:

- Overlooked or misinterpreted signs and symptoms
- Lack of awareness or stigmatization

*Symptoms included are representative and not a complete list

Positive (psychotic)



- Hallucination
- Paranoia
- Exaggerated or distorted perceptions, beliefs and behaviors

Symptoms*

Negative (deficit)



- Impaired emotional expression
- Decreased speech Reduced desire for social
- contact Reduced motivation to pursue purposeful
- activities Decreased experience of pleasure

Click here for additional information on the Positive and Negative Syndrome Scale (PANSS)



Confused and disordered thinking and speech

General

Psychopathology

- Difficulty with logical thinking
- Bizarre behavior or abnormal movements

Acute Phase

Active or Exacerbated Disease

- Initial intervention may involve care from a psychiatrist, a psychologist, a social worker, a case manager, and family
- Initial treatment usually includes a combination of medication, therapy, management strategies, and disease education
- Treatment may need to be adjusted and tailored to the individual
- Poor treatment adherence is associated with poor outcomes:
 - Increased risk of relapse
- Suicidal and aggressive behaviors
- Rehospitalization
- Mortality

Long-term Phase

Maintenance Treatment

- Patients need ongoing support
- Maintaining treatment after symptoms have improved is associated with a reduced risk of relapse
- ▶ Patients may have a shortened life span because of:
 - Accidents and traumatic injuries
 - Comorbid conditions
 - Death due to suicide in ~4-10%

Probability of relapse within 1 year

VS





Medications may cause side effects that need to be considered/managed, some of which may include:



Weight gain



Cardiovascular e.g., hyperlipidemia, tachycardia



Movement disorders



Constipation



Sedation



Endocrine e.g., diabetes mellitus, hyperprolactinemia

Relapse

- Frequent relapses reflect worsening symptoms and may contribute to:
- Neurobiological impairment

medication

- Functional deficits and declining social functioning
- Reduced treatment responsiveness

- ▶ Frequent relapses may trigger:
 - Treatment non-adherence
 - Increased risk of self-injurious behavior
 - Recurrent psychiatric hospitalization
 - Job loss or legal complications

REFERENCES:

1.National Alliance on Mental Illness (NAMI). NAMI. https://www.nami.org/about-mental-illness/mental-health-conditions/schizophrenia/ (accessed August 21, 2025). 2. Cloutier M, Aigbogun MS, Guerin A, et al. J Clin Psychiatry. 2016;77(6):764-771. 3. Vita A, Barlati S, Porcellana M, et al. Front Psychiatry. 2024;15:1382326. 4. National Institute of Mental Health (NIMH). NIMH. https://www.nimh.nih.gov/health/statistics/schizophrenia#part 2715 (accessed August 21, 2025). 5. Moniem I, Kafetzopoulos V. Front Psychiatry. 2025;16:1594334. 6. Mohr P, Galderisi S, Boyer P, et al. Eur Psychiatry. 2018;53:107-115. 7. Treatment Advocacy Center (TAC). TAC. https://www.tac.org/reports_publications/schizophrenia-fact-sheet/ (accessed August 21, 2025). 8. Rivelli A, Fitzpatrick V, Nelson M, et al. Schizophrenia. 2024;10(1):28. 9. The American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. APA. 2021. 10. Mosolov SN, Yaltonskaya PA. Front Psychiatry. 2022;12:766692. 11. Kay SR, Fiszbein A, Opler LA. Schizophr Bull. 1987;13(2):261-276.